Real world study of effectiveness of sunitinib or sorafenib to Chinese unresectable locally advanced or metastatic PRCC

Trial Identifier:	D5086R00001
Sponsor:	AstraZeneca
Start Date:	March 2025
Primary Completion Date:	July 2026
Study Completion Date:	July 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China, shanghai	shanghai, China, 200032

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.